WuXi AppTec opens new medtech testing facility in Suzhou

China flag
The Suzhou center will work with its U.S.-based sister sites in Atlanta and St. Paul, Minnesota. (Shutterstock)

WuXi AppTec opened a new medical device testing facility just outside Shanghai in Suzhou, China, which the contracting giant described as the “full implementation” of its device vision for the Chinese market.

The Suzhou center will work with its U.S.-based testing sites in Atlanta and St. Paul, Minnesota, to form a global medical device testing platform, with services spanning R&D, quality assurance and commercialization.

The new 15,000-square-meter facility will also mirror the capabilities, operations and systems of its U.S.-based sister centers to provide testing services in compliance with international quality standards.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Its offerings will include biomaterials analysis, toxicology, biocompatibility, risk assessment, product aseptic design microbiology, physical testing of packaging and shelf life and product batch release testing, among others.

RELATED: WuXi AppTec warns traders to cool off after 6-fold stock price increase in 3 weeks after its Shanghai IPO

The greater Shanghai area hosts medical device operations from 3M and Medtronic, as well as a Boston Scientific research institute, several domestic companies and manufacturers, alongside several drug makers.

Earlier this year, WuXi AppTec’s contract development and manufacturing subsidiary, STA Pharmaceutical, opened a new R&D center in Shanghai, next door to its production plant. WuXi STA has over 1,000 scientists located at five sites in China and the U.S.—while its parent employs more than 18,000 at over two dozen facilities internationally.

Suggested Articles

Antonio Gualberto, M.D., Ph.D., helped found Kura Oncology and ran its R&D as CMO. Now, he’s moving over to fill the same role at H3 Biomedicine.

One day after its Opdivo-paired prospect flopped, Five Prime is farming out some preclinical antibodies to keep its clinical-stage pipeline alive.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.